scientist using microscope

Insulet (NasdaqGS:PODD) Q3 2020 Earnings Prep


Insulet Corporation (NasdaqGS:PODD) is scheduled to report Q3 earnings results after markets close for trading on November 4, 2020.

The company is expected to report earnings of $0.08/share on revenue of $221.7 million. The consensus earnings per share (EPS) of $0.08/share is based on a poll of 15 analysts and represents a decline in eps of −14.2% over the same quarter last year, when the company reported earnings of $0.09/share.

The revenue forecast of $221.7 million based on a poll of 18 analysts implies a year-over-year (YoY) growth in revenue of 15.4%. Last year the company reported $192.1 million in revenue for the quarter.

Expected to report EPS contraction of −14.2% for Q3, 2020
Metric Expected Prior Year YoY Change
Revenue $221.73 $192.12 15.4%
EPS $0.08 $0.09 −14.2%

Earnings Call Trends

Historically, management has exceeded analyst expectations 4 out of the last 8 tracked quarters, and missed expectations 4 quarters.

What are your expectations from Insulet Corporation for earnings this quarter? Let us know in the comments!

Analyst Expected vs. Reported EPS
Quarter Expected Reported Surprise Result
Q2, 2020 $0.01 $0.22 1,898.2% Beat
Q1, 2020 -$0.02 -$0.03 -94.2% Missed
Q4, 2019 $0.12 $0.10 −15.1% Missed
Q3, 2019 $0.04 $0.09 111.0% Beat
Q2, 2019 $0.03 $0.02 −30.1% Missed
Q1, 2019 $0.01 $0.07 396.1% Beat
Q4, 2018 $0.06 $0.16 167.9% Beat
Q3, 2018 $0.03 $0.03 −6.3% Missed

In the following table, we summarize the company’s stock price movements after earnings releases. The “Price Day Prior” column shows the closing stock price on the day before the earnings report, and the “Price Next Day” column shows the stock price at the end of the trading day after the earnings report. After the last earnings report for the period ending June 30, 2020, the stock price reacted by increasing 1.1%.

Stock Price Performance After Earnings
Report Date Price Day Prior Price Next Day Change % Result
August 6, 2020 $215.32 $217.73 1.1% Increase
May 7, 2020 $206.56 $217.63 5.4% Increase
February 25, 2020 $207.31 $180.01 −13.2% Decline
November 5, 2019 $145.64 $159.99 9.9% Increase

The other question to consider is one of earnings manipulation. There is a lot of pressure on management each quarter to deliver on earnings expectations. The Beneish M-Score is a statistical model that provides some insight into whether the company might be manipulating earnings. With a Beneish M-Score of −2.83, the model suggests that the company is not likely to be an earnings manipulator. A value of −2.83 implies a 0.2% chance of earnings manipulation.

Fundamentals And Technical Analysis

Insulet Corporation is currently trading at $231.72/share, down −5.8% for the day. The company is trading at approximately 90.8% of its 52-week high of $255.39/share. The company’s stock price is up 6.4% since the last earnings report and down −3.9% over the previous week. The company’s 14 Day Relative Price Index (RSI) of 56.99 suggests the company is trading in technically neutral territory. The RSI is considered overbought when above 70 and oversold when below 30.

NasdaqGS:PODD Stock Price Chart
Source: Finbox

The current share price implies a price-to-earnings (P/E) multiple of 840.74 and a forward P/E multiple of 714.72.

Insulet Corporation’s current share price also implies a price-to-book (P/B) multiple of 27.01. The following table summarizes some other key fundamental ratios:

Data as of October 28, 2020
Metric Value
Last Reported Fiscal Period Key FY2020.Q2
Period End Date June 30, 2020
Stock Price (Current) $231.72
P/E Ratio 840.7x
P/E Ratio (Fwd) 714.7x
Price To Sales 18.2x
Total Debt / Total Capital 5.3%
Levered Free Cash Flow -$22.7 million
EV / EBITDA 144.2x


Insulet Corporation is a large-cap stock with a market capitalization of $16.153 billion and a total enterprise value of $16.218 billion. The company operates in the Healthcare sector and the Healthcare Equipment & Supplies industry.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Expertise: financial modeling, mergers & acquisitions. Andy is also a founder at, where he’s focused on building tools that make it faster and easier for investors to do investment research. Andy’s background is in investment banking where he led the analysis on over 50 board advisory engagements involving mergers and acquisitions, fairness opinions and solvency opinions. Some of his board advisory highlights: - Sears Holdings Corp.’s $620 mm spin-off via rights offering of Sears Outlet, Hometown Stores and Sears Hardware Stores. - Cerberus Capital Management’s $3.3 bn acquisition of SUPERVALU Inc.’s New Albertsons, Inc. assets. Andy can be reached at or at +1 (516) 778-6257.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.